
LAVA Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from LAVA Therapeutics N.V.
Access all reports
LAVA Therapeutics N.V. is a biotechnology company focused on developing bispecific gamma-delta T cell engagers (TCEs) for cancer treatment. The company’s proprietary Gammabody platform is designed to activate the immune system by targeting gamma-delta T cells to recognize and destroy tumor cells. LAVA Therapeutics is advancing a pipeline of investigational therapies for hematologic and solid tumors through clinical research and industry collaborations. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the NASDAQ.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
LVTX
Country
🇺🇸 United States